Trial Profile
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Adenocarcinoma; CNS cancer; Glioma; Neuroblastoma; Non-Hodgkin's lymphoma; Rhabdomyosarcoma; Solid tumours
- Focus Therapeutic Use
- Acronyms Pediatric MATCH
- 26 Sep 2023 Planned End Date changed from 30 Jun 2024 to 22 Sep 2024.
- 15 Jul 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
- 17 Nov 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.